Tourists may be shying away from the violence-wracked Holy Land, but the United States Food & Drug Administration has no fear. Representatives of the healthcare watchdog will be visiting in mid-July to inspect Teva Pharmaceuticals (Nasdaq:TEVA) and Biotechnology General (Nasdaq:BTGC), TheMarker has learned.

At Teva, the inspectors will be visiting several departments, including its chemicals and production facilities. The inspection is a routine one carried out every three years, and is expected to last two to three weeks. Teva asked not to comment, adding only that it has excellent relations with the FDA.

BTGC also declined to comment.

No official comment has been available from the FDA regarding its policy on visiting Israel at this time. Israeli companies have said that drug approvals might be kept waiting because of delays in visiting by the regulator.

There had been rumors that the FDA officials might postpone their visit, Teva CFO Dan Suesskind acknowledged a month and a half ago, adding that postponements would not affect Teva in any way at this stage.